Claims
- 1. A drug delivery system comprising a polymeric hydrogel contact lens comprising a beta adrenergic receptor antagonist, or a pharmaceutically acceptable salt thereof, at a concentration of between about 0.25% and 0.000005% by weight absorbed in said contact lens, wherein said beta adrenergic receptor antagonist is capable of being delivered into ocular fluid.
- 2. The drug delivery system of claim 1, wherein said ocular fluid has a pH of between about 7.0-7.4.
- 3. The drug delivery system of claim 1, wherein said polymeric hydrogel contact lens has a water content of between about 10-90% by weight.
- 4. The drug delivery system of claim 1, wherein said polymeric hydrogel contact lens comprises a tetrapolymer of hydroxymethylmethacrylate, ethylene glycol, dimethylmethacrylate, and methacrylic acid.
- 5. The drug delivery system of claim 1, wherein said beta adrenergic receptor antagonist is capable of being transferred into said ocular fluid under ambient conditions.
- 6. The drug delivery system of claim 1, wherein said beta adrenergic receptor antagonist is capable of being transferred into said ocular fluid under existing conditions.
- 7. The drug delivery system of claim 1, wherein said contact lens is capable of correcting vision.
- 8. The drug delivery system of claim 1, wherein said beta adrenergic receptor antagonist is selected from the group consisting of timolol, levobunalol, carteolol, metipranolol, betaxolol, or a pharmaceutically acceptable salt thereof, or combinations thereof.
- 9. The drug delivery system of claim 1, further comprising an alpha adrenergic receptor agonist.
- 10. A drug delivery system comprising a polymeric hydrogel contact lens comprising an alpha adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, at a concentration of between about 0.2% and 0.000002% by weight absorbed in said contact lens, wherein said alpha adrenergic receptor agonist is capable of being delivered into ocular fluid.
- 11. The drug delivery system of claim 10, wherein said ocular fluid has a pH of between about 7.0-7.4.
- 12. The drug delivery system of claim 10, wherein said polymeric hydrogel contact lens has a water content in the range of between about 10-90% by weight.
- 13. The drug delivery system of claim 10, wherein said polymeric hydrogel contact lens comprises a tetrapolymer of hydroxymethylmethacrylate, ethylene glycol, dimethylmethacrylate, and methacrylic acid.
- 14. The drug delivery system of claim 10, wherein said alpha adrenergic receptor agonist is capable of being transferred into said ocular fluid under ambient conditions.
- 15. The drug delivery system of claim 10, wherein said alpha adrenergic receptor agonist is capable of being transferred into said ocular fluid under existing conditions.
- 16. The drug delivery system of claim 10, wherein said contact lens is capable of correcting vision.
- 17. The drug delivery system of claim 10, wherein said alpha adrenergic receptor agonist is selected from the group consisting of brimonidine, apraclonidine, or a pharmaceutically acceptable salt thereof, or combinations thereof.
- 18. The drug delivery system of claim 10, further comprising a beta adrenergic receptor antagonist.
- 19. A method of fabricating a drug delivery system, said method comprising the steps of:
(a) optionally washing a polymeric hydrogel contact lens in a saline solution; (b) at least partially desiccating said lens; and (c) contacting the washed and partially desiccated lens of step (b) in a solution comprising a beta adrenergic receptor antagonist, or a pharmaceutically acceptable salt thereof, at a concentration of about 0.25% to 0.000005% by weight.
- 20. The method of claim 19, wherein said lens is contacted with said solution for at least about 30 minutes.
- 21. The method of claim 19, wherein said solution in step (c) has a pH of between about 7.0-7.4.
- 22. The method of claim 19, wherein said beta adrenergic receptor antagonist is selected from the group consisting of timolol, levobunalol, carteolol, metipranolol, betaxolol, or a pharmaceutically acceptable salt thereof, or combinations thereof.
- 23. A method of fabricating a drug delivery system, said method comprising the steps of:
(a) optionally washing a polymeric hydrogel contact lens in a saline solution; (b) at least partially desiccating said lens; and (c) contacting the washed and partially desiccated lens of step (b) in a solution comprising an alpha adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, at a concentration of about 0.2% to 0.000002% by weight.
- 24. The method of claim 23, wherein said lens is contacted with said solution for at least about 30 minutes.
- 25. The method of claim 23, wherein said solution in step (c) has a pH of between about 7.0-7.4.
- 26. The method of claim 23, wherein said alpha adrenergic receptor agonist is selected from the group consisting of brimonidine, apraclonidine, or a pharmaceutically acceptable salt thereof, or combinations thereof.
- 27. A method of controlling IOP in a mammal comprising contacting a polymeric hydrogel contact lens with the ocular fluid of said mammal, wherein said contact lens comprises a beta adrenergic receptor antagonist, or a pharmaceutically acceptable salt thereof, at a concentration of about 0.25% to 0.000005% by weight.
- 28. The method of claim 27, wherein said IOP is maintained at below about 22 mmHg.
- 29. The method of claim 27, wherein said beta adrenergic receptor antagonist is released such that the concentration of said antagonist in said ocular fluid is approximately constant over a period of at least one day.
- 30. The method of claim 27, wherein said IOP is controlled over a period of at least two days.
- 31. The method of claim 27, wherein said mammal is a human.
- 32. A method of controlling IOP in a mammal comprising contacting a polymeric hydrogel contact lens with the ocular fluid of said mammal, wherein said contact lens comprises an alpha adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, at a concentration of 0.20% to 0.000002% by weight.
- 33. The method of claim 32, wherein said IOP is maintained at below about 22 mmHg.
- 34. The method of claim 32, wherein said alpha adrenergic receptor agonist is released such that the concentration of said agonist in said ocular fluid is approximately constant over a period of at least one day.
- 35. The method of claim 32, wherein said IOP is controlled over a period of at least two days.
- 36. The method of claim 32, wherein said mammal is a human.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. Application Ser. No. 09/507,437, filed Feb. 19, 2000, now U.S. Pat. No. 6,410,045, which claims benefit of U.S. Provisional Application No. 60/121,019, filed Feb. 22, 1999, each of which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60121019 |
Feb 1999 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09507437 |
Feb 2000 |
US |
Child |
10179344 |
Jun 2002 |
US |